RE:FDA Thanks for sharing. However, your estimate of the SP at $ 3 in 2019 seems to me a little optimistic. The launch of Ryplazim during the second half of 2019 means that we will start to see some interesting numbers on the line of revenue in 2020 only. In my humble opinion, it is only then that we will finally be able to see the SP take its true rise. Being a long, I am fine with that.